Media coverage about Obseva (NASDAQ:OBSV) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Obseva earned a news impact score of 0.04 on Accern’s scale. Accern also gave media headlines about the company an impact score of 44.9952328360897 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Obseva (NASDAQ:OBSV) traded down $1.04 on Friday, hitting $11.00. 19,251 shares of the stock traded hands, compared to its average volume of 49,174. Obseva has a 1 year low of $5.00 and a 1 year high of $14.69.
Obseva (NASDAQ:OBSV) last announced its earnings results on Tuesday, November 14th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.01). The business’s revenue for the quarter was up NaN% on a year-over-year basis. analysts anticipate that Obseva will post -2.31 EPS for the current fiscal year.
A number of equities research analysts have issued reports on OBSV shares. HC Wainwright set a $25.00 price target on shares of Obseva and gave the stock a “buy” rating in a report on Wednesday, November 29th. Royal Bank of Canada reaffirmed a “buy” rating and set a $22.00 target price on shares of Obseva in a research note on Thursday, November 2nd. Zacks Investment Research raised shares of Obseva from a “sell” rating to a “buy” rating and set a $11.00 target price on the stock in a research note on Wednesday, October 18th. BMO Capital Markets assumed coverage on shares of Obseva in a research report on Monday, December 4th. They set an “outperform” rating and a $20.00 price target for the company. Finally, Credit Suisse Group began coverage on shares of Obseva in a research report on Monday, October 9th. They set an “outperform” rating and a $16.00 price target for the company. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $19.00.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/04/obseva-obsv-receiving-somewhat-favorable-news-coverage-accern-reports.html.
Obseva Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.